Japan Racing Association (JRA) institute Laboratory for Racing Chemistry testing confirms Arthramid® Vet free of Prohibited Substances in Japan Racing

To provide assurances to veterinarians in Japan, a representative batch of Arthramid® Vet (19F0302) was submitted to the Laboratory of Racing Chemistry (LRC) for analysis.
The LRC was established by the JRA in 1965 as a non-profit foundation dedicated to protecting the integrity of Japanese horse racing from the threat of drug abuse. Arthramid® Vet tested negative to a comprehensive directory of over 105 illegal substances in their List of Prohibited Drugs (Cat. A).

Arthramid® Vet 2.5% Polyacrylamide hydrogel (2.5% PAAG) is an inert, non-pyrogenic and neuro-innocuous polymer gel consisting only of 97.5% sterile water and 2.5% cross-linked polyacrylamide (Contura International A/S, Soborg, Denmark) and contains no active pharmaceutical compound.
Arthramid® Vet is a pioneering intra-articular treatment registered with regulators in New Zealand and Australia for non-infectious osteoarthritis (OA) and degenerative joint disease (DJD) in horses. It has a unique mechanism of action. The advanced gel acts as a “bio-scaffold” that bonds with the injured tissue and strengthens the joint to provide support and better function of movement.

Research suggests 2.5% PAAG is more effective in treating OA than conventional treatments and its adoption by veterinarians will allow a progressive reduction in the use of corticosteroids, such as triamcinolone, and other anti-inflammatories in horse racing and other competitive horse sports.
The product is distributed in New Zealand, Australia, and Asia by Innovative Medical Solutions Limited (IMS).

Managing Director of IMS, Dr Jason Lowe, had this to say about the LRC test results “the tests were requested for the Japanese market in order to provide confirmation that there are no prohibited or unwanted substances present – these negative test results were fully expected. Arthramid® Vet is manufactured to strict European GMP standards in a state-of-the-art manufacturing facility solely dedicated to the production of hydrogels. The quality assurance programme at Contura is as good as it gets, and our international veterinary customers can be assured that every batch of Arthramid® Vet is made with the exact same quality and consistency and is identical to the hydrogels Contura produce for human use”.